BackATAI Life Sciences N.V. Overview

ATAI Life Sciences N.V. Common Stock

ATAI Life Sciences N.V.'s common stock is $3.7M.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$3.69M
84.32% YoYΔ $-19.86M vs prior year quarter

Peer trimmed avg / median

Loading

ATAI Life Sciences N.V. Common Stock History

Loading

ATAI Life Sciences N.V. vs. peers: Common Stock Comparison

Loading

ATAI Life Sciences N.V. Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

ATAI Life Sciences N.V. (ATAI) FAQ

ATAI Life Sciences N.V.'s common stock stands at $3.7M as of June 2026. That compares with $24M in the prior-year period — down 84.3% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

ATAI Life Sciences N.V. reported $3.7M in common stock versus $24M a year earlier — a 84.3% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $24M in the prior-year period — down 84.3% year over year. Sustained growth in common stock can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how ATAI Life Sciences N.V.'s common stock evolved across reporting periods, while the comparison chart places ATAI next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, common stock is commonly used to spot outliers. ATAI Life Sciences N.V.'s reading of $3.7M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.